Status: affected by circulating vaccine-derived poliovirus type 2 (cVDPV2)
In Algeria, circulating vaccine-derived poliovirus type 2 (cVDPV2) has been confirmed.
Polio this week in Algeria
- No case of circulating vaccine-derived poliovirus type 2 (cVDPV2) was reported this week. There is one case in 2022 that is linked to the Zamfara emergence from Nigeria.
- Four cVDPV2 positive environmental samples were reported this week and collected in Tamanghasset.
- The total number of cVDPV2 positive environmental samples in 2022 is 14.
International Health Regulations
Countries affected by poliovirus circulation are subject to temporary recommendations issued by the Emergency Committee of the International Health Regulations on Poliovirus, under the auspices of the Public Health Emergency of International Concern. The latest report by the Committee is effective 1 November 2022.
WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.